End-of-day quote
Korea S.E.
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
614
KRW
|
+3.72%
|
|
+10.63%
|
+53.50%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
52,115
|
88,756
|
143,380
|
122,388
|
44,045
|
57,110
|
Enterprise Value (EV)
1 |
46,163
|
82,977
|
153,583
|
93,005
|
49,346
|
38,063
|
P/E ratio
|
-4.08
x
|
-18.3
x
|
10.8
x
|
15
x
|
-0.88
x
|
-2.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.51
x
|
1.58
x
|
5.33
x
|
6.58
x
|
2.31
x
|
1.02
x
|
EV / Revenue
|
1.34
x
|
1.48
x
|
5.71
x
|
5
x
|
2.58
x
|
0.68
x
|
EV / EBITDA
|
-6.23
x
|
-1,318
x
|
-80.9
x
|
-341
x
|
28.7
x
|
-5.71
x
|
EV / FCF
|
10.8
x
|
-20.7
x
|
7.48
x
|
-5.09
x
|
-2.07
x
|
-7.38
x
|
FCF Yield
|
9.23%
|
-4.83%
|
13.4%
|
-19.6%
|
-48.3%
|
-13.6%
|
Price to Book
|
2.83
x
|
3.5
x
|
1.93
x
|
1.03
x
|
0.5
x
|
0.57
x
|
Nbr of stocks (in thousands)
|
24,296
|
24,896
|
50,397
|
81,321
|
84,703
|
142,775
|
Reference price
2 |
2,145
|
3,565
|
2,845
|
1,505
|
520.0
|
400.0
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/21/22
|
3/22/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
34,472
|
56,155
|
26,896
|
18,613
|
19,098
|
55,750
|
EBITDA
1 |
-7,413
|
-62.96
|
-1,899
|
-272.6
|
1,721
|
-6,669
|
EBIT
1 |
-8,105
|
-347.2
|
-2,156
|
-1,786
|
-240.5
|
-11,404
|
Operating Margin
|
-23.51%
|
-0.62%
|
-8.01%
|
-9.59%
|
-1.26%
|
-20.45%
|
Earnings before Tax (EBT)
1 |
-11,698
|
-3,854
|
12,310
|
7,497
|
-49,555
|
-26,174
|
Net income
1 |
-12,042
|
-4,803
|
11,252
|
7,740
|
-49,555
|
-14,540
|
Net margin
|
-34.93%
|
-8.55%
|
41.84%
|
41.58%
|
-259.47%
|
-26.08%
|
EPS
2 |
-526.0
|
-195.2
|
263.1
|
100.1
|
-591.0
|
-138.0
|
Free Cash Flow
1 |
4,261
|
-4,008
|
20,535
|
-18,274
|
-23,826
|
-5,158
|
FCF margin
|
12.36%
|
-7.14%
|
76.35%
|
-98.18%
|
-124.76%
|
-9.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
182.49%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/21/22
|
3/22/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
10,203
|
-
|
5,301
|
-
|
Net Cash position
1 |
5,951
|
5,779
|
-
|
29,383
|
-
|
19,047
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-5.374
x
|
-
|
3.079
x
|
-
|
Free Cash Flow
1 |
4,261
|
-4,008
|
20,535
|
-18,274
|
-23,826
|
-5,158
|
ROE (net income / shareholders' equity)
|
-61.9%
|
-14.9%
|
20.9%
|
10.1%
|
-39.8%
|
-19.5%
|
ROA (Net income/ Total Assets)
|
-10.3%
|
-0.33%
|
-1.29%
|
-0.71%
|
-0.08%
|
-4.13%
|
Assets
1 |
116,696
|
1,452,311
|
-869,117
|
-1,091,052
|
60,432,580
|
352,081
|
Book Value Per Share
2 |
757.0
|
1,020
|
1,477
|
1,468
|
1,040
|
703.0
|
Cash Flow per Share
2 |
1,449
|
519.0
|
292.0
|
728.0
|
336.0
|
141.0
|
Capex
1 |
119
|
61.7
|
91
|
26.5
|
109
|
535
|
Capex / Sales
|
0.34%
|
0.11%
|
0.34%
|
0.14%
|
0.57%
|
0.96%
|
Announcement Date
|
3/19/19
|
3/17/20
|
3/17/21
|
3/21/22
|
3/22/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| +53.50% | 61.52M | | +23.03% | 72.92B | | -1.52% | 23.8B | | +3.67% | 8.38B | | +8.55% | 8.33B | | -23.71% | 7.66B | | +15.20% | 5.13B | | -6.90% | 4.18B | | +2.68% | 4.06B | | +5.56% | 3.91B |
Pharmaceuticals Wholesale
|